FDA approves first biosimilar to Roche cancer drug Rituxan

Celltrion Inc’s Truxima on Wednesday became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

The approval by the U.S. Food and Drug Administration is part of the agency’s plan to encourage development of cheaper biosimilars amid rising prices of prescription medicines.

Celltrion shares had gained 3.4 percent as of 0023 GMT, versus the wider market’s 1 percent rise.

The FDA has so far approved 14 other biosimilars, including copycats of top-selling drugs like AbbVie Inc’s Humira and Amgen Inc’s Neulasta.

Truxima’s approval was largely expected as the drug had won unanimous backing from an FDA advisory panel in October.

The FDA had earlier declined to approve the drug, citing issues related to a certain manufacturing facility.

Like Rituxan, Truxima’s label contains a boxed warning – the agency’s harshest – that highlights several health risks including a rare, serious brain infection and liver damage.

Drugmakers are only able to produce biosimilar versions of complex drugs such as Rituxan since the molecules are made inside living cells and cannot be exactly replicated.

Truxima, already approved in Europe, will be sold in the United States and Canada in partnership with Israel’s Teva Pharmaceutical Industries.

“With this approval, Celltrion has entered the United States, the world’s biggest Rituxan market, as the first mover and expects to gain a fairly early edge in the market,” Celltrion said in a statement.

Roche’s drug, approved in 1997, is marketed as Rituxan in the United States, Japan and Canada and as MabThera elsewhere.

Apart from Rituxan, Roche, the world’s biggest producer of cancer drugs, is also facing competition from cut-price biosimilars of its two other best-selling drugs Herceptin and Avastin. The Swiss-based drugmaker has stepped up cost cuts in an efficiency drive to cushion the blow.

Earlier this month, Novartis International AG said it would no longer pursue U.S. regulatory approval for its biosimilar of Rituxan after the FDA sought additional information.

  • Related Posts

    • Pharma
    • March 27, 2024
    • 96 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 66 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down